Branch of Guangzhou Baiyunshan Pharmaceutical Holdings (00874), Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical General Factory has obtained drug supplementary application approval.
Baiyunshan (00874) announced that recently, the company's subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., Baiyunshan Pharmaceutical...
Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. (referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory") recently received the "Drug Supplementary Application Approval Notification" issued by the National Medical Products Administration.
The announcement stated that Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Factory has obtained the "Drug Supplementary Application Approval Notification" for Fuke'an Tablets, Kunling Pills, Shenxi Dan, Yiganling Tablets, and Maian Granules, which enhances the safety information of these drugs and contributes to their safe, effective, and rational use, thereby improving the market competitiveness of the products. The receipt of the "Drug Supplementary Application Approval Notification" this time will not have a significant impact on the company's current performance.
Related Articles
YEE HOP HLDGS (01662) intends to subscribe for Trio AI with a capital of 15 million Hong Kong dollars, increasing its issued capital by approximately 51.73%.
YEE HOP Holdings (01662) plans to offer a discount of approximately 12.96% for the rights issue, with a maximum net funds raised of approximately HK$34.97 million. Trading will resume on September 17th.
E Fund Management Co. reduced its holdings of Hangzhou Tigermed Consulting (03347) by 4.17 million shares at a price of approximately HK$44.34 per share.
YEE HOP HLDGS (01662) intends to subscribe for Trio AI with a capital of 15 million Hong Kong dollars, increasing its issued capital by approximately 51.73%.
YEE HOP Holdings (01662) plans to offer a discount of approximately 12.96% for the rights issue, with a maximum net funds raised of approximately HK$34.97 million. Trading will resume on September 17th.
E Fund Management Co. reduced its holdings of Hangzhou Tigermed Consulting (03347) by 4.17 million shares at a price of approximately HK$44.34 per share.
